Anti-ACVR1/ ALK-2/ ACTRIA monoclonal antibody
Anti-ACVR1/ ALK-2/ ACTRIA antibody for FACS & in-vivo assay
Go to ALK-2/ACVR1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T12091-Ab-1/ GM-Tg-hg-T12091-Ab-2 | Anti-Human ALK-2/ACVR1 monoclonal antibody | Human |
GM-Tg-rg-T12091-Ab-1/ GM-Tg-rg-T12091-Ab-2 | Anti-Rat ALK-2/ACVR1 monoclonal antibody | Rat |
GM-Tg-mg-T12091-Ab-1/ GM-Tg-mg-T12091-Ab-2 | Anti-Mouse ALK-2/ACVR1 monoclonal antibody | Mouse |
GM-Tg-cynog-T12091-Ab-1/ GM-Tg-cynog-T12091-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ALK-2/ACVR1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T12091-Ab-1/ GM-Tg-felg-T12091-Ab-2 | Anti-Feline ALK-2/ACVR1 monoclonal antibody | Feline |
GM-Tg-cang-T12091-Ab-1/ GM-Tg-cang-T12091-Ab-2 | Anti-Canine ALK-2/ACVR1 monoclonal antibody | Canine |
GM-Tg-bovg-T12091-Ab-1/ GM-Tg-bovg-T12091-Ab-2 | Anti-Bovine ALK-2/ACVR1 monoclonal antibody | Bovine |
GM-Tg-equg-T12091-Ab-1/ GM-Tg-equg-T12091-Ab-2 | Anti-Equine ALK-2/ACVR1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T12091-Ab-1/ GM-Tg-hg-T12091-Ab-2; GM-Tg-rg-T12091-Ab-1/ GM-Tg-rg-T12091-Ab-2; GM-Tg-mg-T12091-Ab-1/ GM-Tg-mg-T12091-Ab-2; GM-Tg-cynog-T12091-Ab-1/ GM-Tg-cynog-T12091-Ab-2; GM-Tg-felg-T12091-Ab-1/ GM-Tg-felg-T12091-Ab-2; GM-Tg-cang-T12091-Ab-1/ GM-Tg-cang-T12091-Ab-2; GM-Tg-bovg-T12091-Ab-1/ GM-Tg-bovg-T12091-Ab-2; GM-Tg-equg-T12091-Ab-1/ GM-Tg-equg-T12091-Ab-2 |
Products Name | Anti-ALK-2/ACVR1 monoclonal antibody |
Format | mab |
Target Name | ALK-2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ALK-2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ACVR1/ ALK-2/ ACTRIA VLP (virus-like particle) (Products Developing) |
Cytokine | GM-Tg-g-T12091-Ag-1 | activin A receptor, type I (ACVR1) protein |
ORF Viral Vector | vGMAD000055 | human ACVR1 Adenovirus particle |
ORF Viral Vector | pGMAD000055 | human ACVR1 Adenovirus plasmid |
ORF Viral Vector | pGMLPm003206 | mouse Acvr1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm003206 | mouse Acvr1 Lentivirus particle |
Target information
Target ID | GM-T12091 |
Target Name | ALK-2 |
Gene ID | 90,11477,79558,697935,478757,101091298,338068,100050899 |
Gene Symbol and Synonyms | ActR-I,ActR-IA,ACTRI,ActRIA,Acvr,ACVR1,ACVR1A,ACVRLK2,Alk-2,ALK2,Alk8,D330013D15Rik,FOP,SKR1,Tsk7L,TSRI |
Uniprot Accession | Q04771,P80201,Q28041 |
Uniprot Entry Name | ACVR1_HUMAN,ACVR1_RAT,ACVR1_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Cytokine Target |
Disease | N/A |
Gene Ensembl | ENSG00000115170 |
Target Classification | Kinase |
The target: ALK-2, gene name: ACVR1, also named as ACTRIA, ACVRLK2, ALK2, FOP, SKR1, TSRI, ACVR1. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.